||Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer
Tamura, Tomohiro ,
Kurishima, Koichi ,
Nakazawa, Kensuke ,
Ishikawa, Hiroichi ,
Satoh, HiroakiHizawa, Nobuyuki
1140 , 2015-08 , Spandidos Publications
The present study aimed to evaluate the similar survival benefits of a good response [complete response or partial response (CR/PR)] and stable disease (SD) to chemotherapy in non‑small cell lung cancer (NSCLC) patients in clinical practice. All 322 patients who were treated between 1999 and 2012 with first‑line platinum‑based chemotherapy were retrospectively analyzed. Tumor responses were classified according to the response evaluation criteria for solid tumors. A total of 67 (20.8%) patients experienced CR/PR and 165 (51.2%) achieved SD. There was no difference in progression‑free survival between the patients with CR/PR and those with SD (P=0.347). There was also no difference between the two groups with regard to overall survival time (P=0.878). In multivariate analysis, disease‑control (more than SD) was one of the favorable prognostic factors. In clinical practice, a survival benefit would be provided not only for the patients who have good response, but also for those with SD.